Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Long-Term Safety and Efficacy Extension Study in Subjects With Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Previously Enrolled in UX007 or Triheptanoin Studies

NCT02214160 is registered in ClinicalTrials.gov with Ultragenyx Pharmaceutical Inc as lead sponsor.

NCT NCT02214160
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02214160 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Long-Term Safety and Efficacy Extension Study in Subjects With Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Previously Enrolled in UX007 or Triheptanoin Studies
Lead sponsor
Ultragenyx Pharmaceutical Inc
Phase
Phase 2
Overall status
Completed
Start date
December 9, 2014
Completion date
December 3, 2020
Enrollment
94 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

carnitine palmitoyltransferase (cpt i or cpt ii) deficiency, carnitine-acylcarnitine translocase (cact) deficiency, long-chain 3-hydroxy-acyl-coa dehydrogenase (lchad) deficiency, trifunctional protein (tfp) deficiency, very long chain acyl-coa dehydrogenase (vlcad) deficiency